These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 26562248)
1. Combined Ang-2 and VEGF serum levels: holding hands as a new integral biomarker in non-small-cell lung cancers. Coelho AL; Araújo AM; Gomes MP; Catarino RJ; Andrade EB; Lopes AM; Medeiros RM Future Oncol; 2015; 11(24):3233-42. PubMed ID: 26562248 [TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of serum vascular endothelial growth factor and Angiopoietin-2 in patients with lung cancer. Akın Kabalak P; Çiledağ A; Demir N; Çelik G; Yüksel C; Köycü G; Gökmen Öztuna D; Taner A; Kaya A; Kutlay H; Numanoğlu N; Savaş İ Tuberk Toraks; 2015 Jun; 63(2):71-7. PubMed ID: 26167963 [TBL] [Abstract][Full Text] [Related]
3. Angiogenic axis angiopoietin-1 and angiopoietin-2/Tie-2 in non-small cell lung cancer: a bronchoalveolar lavage and serum study. Naumnik W; Naumnik B; Niewiarowska K; Ossolinska M; Chyczewska E Adv Exp Med Biol; 2013; 788():341-8. PubMed ID: 23835996 [TBL] [Abstract][Full Text] [Related]
4. Serum angiopoietin-2 as a clinical marker for lung cancer. Park JH; Park KJ; Kim YS; Sheen SS; Lee KS; Lee HN; Oh YJ; Hwang SC Chest; 2007 Jul; 132(1):200-6. PubMed ID: 17505039 [TBL] [Abstract][Full Text] [Related]
5. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607 [TBL] [Abstract][Full Text] [Related]
6. Serum Angiopoietin-2 as a Clinical Marker for Lung Cancer in Patients with Solitary Pulmonary Nodules. Xu C; Wang W; Wang Y; Zhang X; Yan J; Yu L Ann Clin Lab Sci; 2016; 46(1):60-4. PubMed ID: 26927344 [TBL] [Abstract][Full Text] [Related]
7. Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer. Park JH; Choi H; Kim YB; Kim YS; Sheen SS; Choi JH; Lee HL; Lee KS; Chung WY; Lee S; Park KJ; Hwang SC; Lee KB; Park KJ Lung Cancer; 2009 Dec; 66(3):359-64. PubMed ID: 19339077 [TBL] [Abstract][Full Text] [Related]
8. Effects of microwave ablation or its combination with whole-body chemotherapy on serum vascular endothelial growth factor levels in patients with stage IIIB/IV NSCLC. Sun YH; Song PY; Guo Y; Pang M; He WN; Zhang WH; Sheng LJ Genet Mol Res; 2015 Aug; 14(3):10015-25. PubMed ID: 26345938 [TBL] [Abstract][Full Text] [Related]
9. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461 [TBL] [Abstract][Full Text] [Related]
10. Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected]. Coelho AL; Araújo A; Gomes M; Catarino R; Marques A; Medeiros R PLoS One; 2014; 9(2):e90009. PubMed ID: 24587185 [TBL] [Abstract][Full Text] [Related]
11. Prognostic impacts of angiopoietins in NSCLC tumor cells and stroma: VEGF-A impact is strongly associated with Ang-2. Andersen S; Donnem T; Al-Shibli K; Al-Saad S; Stenvold H; Busund LT; Bremnes RM PLoS One; 2011; 6(5):e19773. PubMed ID: 21603628 [TBL] [Abstract][Full Text] [Related]
12. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. Jantus-Lewintre E; Sanmartín E; Sirera R; Blasco A; Sanchez JJ; Tarón M; Rosell R; Camps C Lung Cancer; 2011 Nov; 74(2):326-31. PubMed ID: 21481963 [TBL] [Abstract][Full Text] [Related]
13. Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable non-small cell lung cancer. Hu Y; Hu MM; Shi GL; Han Y; Li BL Eur J Surg Oncol; 2014 Sep; 40(9):1136-42. PubMed ID: 24998915 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis. Xuan ZX; Zhang S; Yuan SJ; Wang W; Yu J World J Surg Oncol; 2016 Sep; 14(1):237. PubMed ID: 27589869 [TBL] [Abstract][Full Text] [Related]
15. Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer. Li M; Zhang Q; Wu L; Jia C; Shi F; Li S; Peng A; Zhang G; Song X; Wang C Oncol Rep; 2014 Apr; 31(4):1961-7. PubMed ID: 24549225 [TBL] [Abstract][Full Text] [Related]
16. Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy. Naumnik W; Nilklińska W; Ossolińska M; Chyczewska E Folia Histochem Cytobiol; 2009; 47(4):703-9. PubMed ID: 20430742 [TBL] [Abstract][Full Text] [Related]
17. Serum reactive oxygen species modulator 1 (Romo1) as a potential diagnostic biomarker for non-small cell lung cancer. Lee SH; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kang KH; In KH Lung Cancer; 2014 Aug; 85(2):175-81. PubMed ID: 24951318 [TBL] [Abstract][Full Text] [Related]
18. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Shimanuki Y; Takahashi K; Cui R; Hori S; Takahashi F; Miyamoto H; Fukurchi Y Lung; 2005; 183(1):29-42. PubMed ID: 15793665 [TBL] [Abstract][Full Text] [Related]
19. [The evaluation to relationship between serum vascular endothelial growth factor (VEGF) level, metastases and other tumor markers in patients with lung cancer]. Sağlam DA; Ursavaş A; Karadağ M; Yilmaztepe Oral A; Coşkun F; Gözü RO Tuberk Toraks; 2008; 56(1):50-5. PubMed ID: 18330755 [TBL] [Abstract][Full Text] [Related]
20. Serum levels of angiopoietin-1, angiopoietin-2, and their receptor tie-2 in patients with nonsmall cell lung cancer during chemotherapy. Naumnik W; Chyczewska E; Ossolinska M Cancer Invest; 2009 Aug; 27(7):741-6. PubMed ID: 19340656 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]